NYSE · TAK
Takeda Pharmaceutical Company Limited American (each representing 1/2 of a of )
$17.24 +$0.42 (+2.50%) 1D After hours
Session Pulse
After hours
1
mentions on Wed
· 1 bullish
/ 0 bearish tags
No new SEC filings since Mon close
Full pulse →
Key Metrics
$53.71B
Market cap
—
P/E · TTM
—
Revenue · TTM
—
Net income
EPS · TTM
—
Dividend yield
—
Free cash flow
—
Beta · 1Y
0.26
EBITDA · TTM
—
Gross margin
—
Snapshot
Market cap$53.71B
Enterprise value—
Shares outstanding3.2B
52-wk range$12.99 – $18.90
Avg volume · 20D2.5M
Net cash
—
Book value / share—
ExchangeNYSE
About Takeda Pharmaceutical Company Limited American (each representing 1/2 of a of )
IPO dateMar 7, 2008
Employees47029
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue.
Wolf Grade COMING SOON
—
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.
Valuation
P/E—
P/S—
P/FCF—
EV/EBITDA—
EV/Sales—
Graham №—
Profitability
Gross
—
Operating
—
Net
—
FCF
—
ROE / ROIC
— · —
Financial Health
Current ratio—
Quick ratio—
Debt / equity—
Debt / EBITDA
—
Net cash
—
Working capital—
Cash Flow · TTM
Operating CF
—
Capex
—
Free cash flow
—
Buybacks
—
Dividends paid
—
Shareholder yield
—
Piotroski F-Score
0 / 9
Weak fundamentals · 0 of 9 signals passing
Altman Z-Score
—
Insufficient balance-sheet inputs
Graham Number vs Price
—
Requires positive earnings and book value
Fundamentals through 2025-03-31 · computed by TickerWolf from SEC filings